BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12613519)

  • 1. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group.
    Krupicka J; Marková J; Pohlreich D; Kozák T; Línková H; Diehl V;
    Leuk Lymphoma; 2002 Dec; 43(12):2325-9. PubMed ID: 12613519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic evaluation of early and chronic cardiotoxicity in adult patients treated for Hodgkin's disease with ABVD regimen.
    Elbl L; Vasova I; Kral Z; Navratil M; Smardova L; Vorlicek J
    Neoplasma; 2006; 53(1):62-6. PubMed ID: 16416015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease.
    Constine LS; Schwartz RG; Savage DE; King V; Muhs A
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):897-906. PubMed ID: 9369139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy.
    Tsai HR; Gjesdal O; Wethal T; Haugaa KH; Fosså A; Fosså SD; Edvardsen T
    Am J Cardiol; 2011 Feb; 107(3):472-7. PubMed ID: 21257017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease.
    Kreuser ED; Völler H; Behles C; Schröder K; Uhrig A; Besserer A; Thiel E
    Br J Haematol; 1993 Aug; 84(4):615-22. PubMed ID: 8217818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
    Elbl L; Vasova I; Kral Z; Tomaskova I; Smardova L; Wagnerova B; Jedlicka F; Vorlicek J
    J Chemother; 2006 Apr; 18(2):199-208. PubMed ID: 16736890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The late cardiac sequelae after mantle-field irradiation. The results in Erlangen's patient caseload].
    Friedrich SA; Unverdorben M; Kunkel B; Dunst J
    Strahlenther Onkol; 1996 Jan; 172(1):19-24. PubMed ID: 8571182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up.
    Zsáry A; Szücs S; Keltai K; Pásztor E; Schneider T; Rosta A; Sármán P; Jánoskuti L; Fenyvesi T; Karádi I
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S372-5. PubMed ID: 15838323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
    Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
    Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late cardiotoxicity after treatment for a malignant bone tumor.
    Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
    Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of epirubicin on left ventricular function in patients with malignant lymphoma].
    Usnarska-Zubkiewicz L; Nowosad H; Grzelak H; Kostecki E; Kotlarek-Haus S
    Pol Arch Med Wewn; 1994 Oct; 92(4):322-30. PubMed ID: 7854960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma.
    Krawczuk-Rybak M; Dakowicz L; Hryniewicz A; Maksymiuk A; Zelazowska-Rutkowska B; Wysocka J
    J Paediatr Child Health; 2011 Jul; 47(7):455-9. PubMed ID: 21332587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
    Avilés A; Neri N; Nambo JM; Huerta-Guzman J; Talavera A; Cleto S
    Leuk Lymphoma; 2005 Jul; 46(7):1023-8. PubMed ID: 16019553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
    von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
    Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.